Muscle Health Biomarkers
TL;DR
No single blood biomarker independently confirms muscle health. Cystatin C is preferred over creatinine because it is independent of muscle mass and has a stable production rate. The Sarcopenia Index (SCr / s-CysC × 100) offers moderate screening utility (AUC 0.64–0.73) but is not a standalone diagnostic. IGF-1 requires standardized morning fasting draws due to ~30% diurnal variation. 3-methylhistidine is not practical for coaching (requires 5-day creatine-free diet + 24-hour urine collection). Creatinine alone is insufficient during GLP-1 therapy due to confounding from both renal hemodynamic effects and changing muscle mass.
Cystatin C — Preferred Biomarker
Key properties
- Half-life: ~2 hours — 3× shorter than creatinine’s ~6 hours (PMC4309632)
- Independence from muscle mass: Serum cystatin C does NOT correlate with lean mass; serum creatinine does (PMC2390952)
- Production rate: 0.124 ± 0.023 mg/min/1.73 m² — stable, not affected by diet or physical activity
- Reference ranges: Adults <50 years: 0.53–0.95 mg/L; adults >50 years: 0.58–1.02 mg/L (PMID:10672373)
- Age drift: Mean cystatin C increases 46% from age <40 (0.72 mg/L) to ≥80 (1.06 mg/L) even in healthy adults without kidney disease (PMC2904248)
Sarcopenia Index (SI)
Formula: SI = (SCr / s-CysC) × 100
| Validation study | Population | AUC (males) | Notes |
|---|---|---|---|
| UK Biobank (n=458,702; PMID:38968079) | Broad adult cohort | 0.731 | Every 1-unit SI increase → 5% lower odds of confirmed sarcopenia |
| Community-dwelling older adults (NATURE-SARCO-2018) | Healthy older adults | 0.64–0.72 | Contested in those with normal renal function |
Best use for Vitals: Longitudinal SI trend tracking. Useful for screening but not a standalone diagnostic — combine with grip strength, BIA ALM trend, and functional measures.
Why preferred over creatinine during GLP-1 therapy
Creatinine is produced from the muscle creatine pool. As lean mass falls during GLP-1 therapy, serum creatinine falls — this can falsely suggest normal kidney function when true kidney function is declining or when muscle is being lost independently. Cystatin C is not derived from muscle and is not affected by these changes.
Creatinine
Key properties
- Daily production: 150–200 μmol/kg/day in adult males
- Muscle mass correlation: 1 g creatinine/24h ≈ 22.7 kg skeletal muscle (PMC6816842)
- Half-life: ~6 hours
Confounding during GLP-1 therapy
- Retatrutide affects renal hemodynamics via SGLT2-like effects — creatinine-based eGFR may not reflect true renal function
- Muscle mass loss reduces creatinine production independently of kidney function
- Net effect: Creatinine can simultaneously overstate kidney function (via hemodynamic effect) and understate muscle loss — doubly confounded
Verdict for Vitals
Creatinine alone is insufficient for muscle health monitoring during GLP-1 therapy. Use cystatin C instead or simultaneously. Track both, but weight cystatin C for muscle health inference.
IGF-1 (Insulin-like Growth Factor 1)
Pharmacokinetic properties
| Form | Half-life | Notes |
|---|---|---|
| Ternary complex (IGF-1 + IGFBP-3 + ALS) | 12–15 hours | Primary circulating form in healthy adult males |
| Free IGF-1 | 10–12 minutes | Biologically active fraction |
| Binary complex (IGF-1 + IGFBP) | 20–30 minutes | Intermediate pool |
| Subcutaneous rhIGF-1 | ~20 hours | Bioavailability ~100% |
Source: PMID:2558477 (tracer study); PMID:8219484
Endogenous production rate: ~10 mg/day (PMID:2558477)
Diurnal variation
IGF-1 shows ~30% diurnal variation — morning fasting samples required for comparable results. Afternoon samples may be 20–30% lower. This is a Confirmed fact (PMID:2558477).
Clinical use for sarcopenia
- Low IGF-1 is associated with sarcopenia in elderly populations
- No standardized clinical cut-off for IGF-1 in sarcopenia diagnosis
- Single time-point measurement is unreliable without standardized sampling
- IGF-1 is more useful as a trend monitor than a single value
Vitals coaching use
- Order IGF-1 as a morning fasting draw every 3–6 months
- Track trend, not single values
- Decline >15% from baseline warrants nutritional/muscle health review
- Standardize to AM draws only — afternoon values are not comparable
3-Methylhistidine (3MH) — Not Recommended
What it is
Amino acid released from actin and myosin during myofibrillar protein breakdown; excreted in urine.
Properties
- Human fractional breakdown rate: ~2.16%/day of myofibrillar protein pool (PMID:750147)
- Daily excretion (adult males, creatine-free diet): 211 μmol/day (range 167–252) (PMID:642824)
- Time to plateau on creatine-free diet: 5 days (PMID:750147)
Why it is impractical for coaching
Requires:
- Quantitative 24-hour urine collection (not spot urine)
- 5+ days of creatine-free diet (meat and fish contain creatine → dietary 3MH inflates values)
- Gut actin contributes to urinary 3MH independently of muscle breakdown
Verdict: Not practical for routine coaching. Only appropriate for research settings. Recommend against for Vitals implementation.
Monitoring Protocol for GLP-1 Users
Recommended panel
| Biomarker | Frequency | Notes |
|---|---|---|
| Cystatin C | Every 3 months | Calculate Sarcopenia Index (SCr/s-CysC × 100) trend; independent of muscle mass |
| IGF-1 | Every 6 months | Morning fasting draw required; track trend, not single value |
| Creatinine | Every 3 months (standard GLP-1 monitoring) | Note: confounded by retatrutide renal effects and muscle mass changes; use cystatin C for inference |
| BIA ALM (Withings Body Scan or equivalent) | Monthly | Track trend; trigger DXA if >5% loss in 30 days or approaching <20 kg (men) |
| Grip strength (GripAble/CAMRY) | Monthly | Track trend; >10% decline from baseline triggers check-in |
| iPhone gait speed | Passive continuous | Review 90-day rolling average monthly |
Biomarkers NOT recommended for routine Vitals coaching
- 3-methylhistidine: Impractical (requires 5-day diet restriction + 24h urine)
- Standard DEXA for frequent monitoring: LSC 3.85–19.4% means frequent scans are not informative; use DXA for baseline and Tier 3 referral only
Key PMIDs
| PMID | Topic |
|---|---|
| 38968079 | Sarcopenia Index validation (UK Biobank) |
| PMC4309632 | Cystatin C half-life ~2h |
| PMC2390952 | Cystatin C independent of muscle mass |
| PMC6816842 | Creatinine-muscle mass correlation |
| PMC2904248 | Cystatin C age drift |
| 10672373 | Cystatin C reference ranges by age |
| 2558477 | IGF-1 half-life 12–15h (bound); diurnal variation |
| 8219484 | rhIGF-1 SC half-life ~20h |
| 750147 | 3MH fractional breakdown rate 2.16%/day |
| 642824 | 3MH daily excretion reference values |
Related notes
- Sarcopenia Detection — parent hub
- Sarcopenia Diagnostic Criteria — DXA, BIA, grip strength, gait speed details
- Blood Biomarker Optimization — broader biomarker framework; IGF-1 also tracked there
- GLP-1 Muscle Preservation — GLP-1-specific muscle loss context; references cystatin C creatinine artifact
- HRV — HRV as general recovery/biometric signal